A Study Of Diflucan In Children With Ringworm Of The Scalp
NCT ID: NCT00645242
Last Updated: 2021-07-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
185 participants
INTERVENTIONAL
2002-11-30
2003-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Diflucan Research For Infant Evaluation Of Antifungal Treatment And Prophylaxis Medication
NCT01680458
Voriconazole to Prevent Systemic Fungal Infections in Children
NCT00005912
Fluconazole Versus Micafungin in Neonates With Candidiasis
NCT02145832
Documented Candida or Aspergillus Infections in Pediatric Patients (0991-043)
NCT00082524
Fluconazole Pharmacokinetics in Infants
NCT00514358
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm A
fluconazole
Fluconazole oral suspension 6 mg/kg/day for 6 weeks followed by 4 weeks without treatment
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
fluconazole
Fluconazole oral suspension 6 mg/kg/day for 6 weeks followed by 4 weeks without treatment
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Clinical diagnosis of tinea capitis
* Direct microscopy (KOH) positive for fungal elements within or outside hair shaft
Exclusion Criteria
* Liver disease
3 Years
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Montgomery, Alabama, United States
Pfizer Investigational Site
Little Rock, Arkansas, United States
Pfizer Investigational Site
San Diego, California, United States
Pfizer Investigational Site
Miami, Florida, United States
Pfizer Investigational Site
Miami, Florida, United States
Pfizer Investigational Site
Martinez, Georgia, United States
Pfizer Investigational Site
Chicago, Illinois, United States
Pfizer Investigational Site
Evanston, Illinois, United States
Pfizer Investigational Site
Gretna, Louisiana, United States
Pfizer Investigational Site
New Orleans, Louisiana, United States
Pfizer Investigational Site
Shreveport, Louisiana, United States
Pfizer Investigational Site
Detroit, Michigan, United States
Pfizer Investigational Site
Fridley, Minnesota, United States
Pfizer Investigational Site
Bridgeton, Missouri, United States
Pfizer Investigational Site
Brooklyn, New York, United States
Pfizer Investigational Site
Garner, North Carolina, United States
Pfizer Investigational Site
Raleigh, North Carolina, United States
Pfizer Investigational Site
Cleveland, Ohio, United States
Pfizer Investigational Site
Columbus, Ohio, United States
Pfizer Investigational Site
Mt. Pleasant, South Carolina, United States
Pfizer Investigational Site
Knoxville, Tennessee, United States
Pfizer Investigational Site
Murfreesboro, Tennessee, United States
Pfizer Investigational Site
Nashville, Tennessee, United States
Pfizer Investigational Site
Houston, Texas, United States
Pfizer Investigational Site
San Antonio, Texas, United States
Pfizer Investigational Site
San Antonio, Texas, United States
Pfizer Investigational Site
San Antonio, Texas, United States
Pfizer Investigational Site
Norfolk, Virginia, United States
Pfizer Investigational Site
Carolina, , Puerto Rico
Pfizer Investigational Site
Ponce, , Puerto Rico
Pfizer Investigational Site
Ponce, , Puerto Rico
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A0561017
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.